.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Boehringer Ingelheim
Medtronic
Johnson and Johnson
Citi
Fuji
UBS
Cerilliant
Baxter

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022522

« Back to Dashboard
NDA 022522 describes DALIRESP, which is a drug marketed by Astrazeneca Pharms and is included in one NDA. It is available from three suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DALIRESP profile page.

The generic ingredient in DALIRESP is roflumilast. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the roflumilast profile page.

Summary for NDA: 022522

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:6

Pharmacology for NDA: 022522

Mechanism of ActionPhosphodiesterase 4 Inhibitors

Suppliers and Packaging for NDA: 022522

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DALIRESP
roflumilast
 TABLET;ORAL 022522 NDA AstraZeneca Pharmaceuticals LP 0310-0095 0310-0095-30 30 TABLET in 1 BOTTLE, PLASTIC (0310-0095-30)
DALIRESP
roflumilast
 TABLET;ORAL 022522 NDA AstraZeneca Pharmaceuticals LP 0310-0095 0310-0095-39 10 BLISTER PACK in 1 BOX, UNIT-DOSE (0310-0095-39) > 2 TABLET in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MCG
Approval Date:Feb 28, 2011TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 31, 2020
Regulatory Exclusivity Use:
Patent:► SubscribePatent Expiration:Jan 27, 2020Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
Patent:► SubscribePatent Expiration:Feb 19, 2023Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Argus Health
Johnson and Johnson
Farmers Insurance
Fish and Richardson
Queensland Health
Fuji
Boehringer Ingelheim
Baxter
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot